A pre-administration feasibility pharmacokinetic and meal study of hyaluronidase administered as a single dose prior to subcutaneous infusion of insulin aspart in patients with type 1 diabetes.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2011
At a glance
- Drugs Hyaluronidase; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- 01 Nov 2011 Status changed from active, no longer recruiting to completed.
- 27 Oct 2011 New trial record
- 21 Oct 2011 Results from this trial will be presented at the Diabetes Technology Meeting in October 2011, according to a Halozyme Therapeutics media release.